Loading
A phase 1/2 trial of HMBD-001, Docetaxel, Cetuximab in non-small-cell lung cancer and small-cell lung cancer, run by Hummingbird Bioscience, now recruiting.
A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers is a phase 1/2 interventional study registered as NCT05910827 by Hummingbird Bioscience, with 398 participants planned, started 2024-02-05 and due to reach its primary completion in 2027-12-01. Interventions recorded: HMBD-001, Docetaxel, Cetuximab. Conditions listed: Advanced or Metastatic Squamous Non-Small Cell Lung Cancer, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Esophageal Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Hummingbird Bioscience, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Cetuximab, Docetaxel, Head and neck squamous cell carcinoma, Small-cell lung cancer.
Shares Cetuximab, Monoclonal antibodies, Head and neck squamous cell carcinoma.
Shares Docetaxel, Small-cell lung cancer, Cytotoxic chemotherapy, Non-small-cell lung cancer.
Shares Cutaneous squamous cell carcinoma, Head and neck squamous cell carcinoma, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Docetaxel, Small-cell lung cancer, Cytotoxic chemotherapy, Non-small-cell lung cancer.
Shares Cetuximab, Monoclonal antibodies, Head and neck squamous cell carcinoma.
Shares Docetaxel, Small-cell lung cancer, Cytotoxic chemotherapy, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/